INDIANAPOLIS, June 11, 2018 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) announced today it will present new data from
its immunology portfolio, including cornerstone treatments
OLUMIANT® (baricitinib) and Taltz®
(ixekizumab), at the Annual European Congress of Rheumatology
(EULAR 2018) in Amsterdam from
June 13-16, 2018. Highlights for
baricitinib include results from a global Phase 2 study evaluating
the safety and efficacy of two doses of baricitinib for the
treatment of systemic lupus erythematosus (SLE), which will be
featured in a podium presentation on Wednesday, June 13 from 4:15-5:45 PM CET and highlighted as part of a
EULAR press conference on Thursday, June 14,
2018 from 9-10 AM CET.
Highlights for Taltz at EULAR include three-year safety and
efficacy data from SPIRIT-P1, a Phase 3 study evaluating Taltz for
the treatment of psoriatic arthritis in patients naïve to biologic
treatment.
"The data being presented at EULAR demonstrate Lilly's
commitment to developing treatment advancements to help patients
with severe auto-immune diseases," said Lotus Mallbris, M.D.,
global head of immunology product development, Lilly Bio-Medicines.
"We are excited to be sharing data evaluating baricitinib as a
potential treatment for systemic lupus erythematosus, underscoring
the potential of our immunology portfolio."
OLUMIANT is featured in 10 additional abstracts discussing
efficacy and safety results in the treatment of rheumatoid
arthritis (Lilly and Incyte Corporation (NASDAQ: INCY) are partners
in the development of baricitinib). Eight abstracts evaluating the
efficacy and safety of Taltz for the treatment of active
psoriatic arthritis will also be presented. Ten additional
abstracts will detail results from a selection of studies
evaluating the impact of immune-mediated diseases on patients,
including rheumatoid arthritis, psoriatic arthritis and SLE.
Studies, as well as dates and times of the data sessions, are
highlighted below.
Baricitinib Data
Wednesday, June 13, 16:15 –
17:45 CET – PODIUM PRESENTATION
- Baricitinib in Systemic Lupus Erythematosus (SLE): Results from
a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
(Presenting author: Daniel Wallace)
Abstract: OP0019
Thursday, June 14, 11:45 –
13:30 CET – POSTER PRESENTATIONS
- Converting Patient-Reported Outcome Measures of Fatigue and
Pain to PROMIS Scores: Data from Phase 3 Baricitinib Rheumatoid
Arthritis Trials (Presenting author: Bing Bingham) Abstract:
THU0106
- Autoantibody Profiling for Response to Baricitinib in Patients
with Rheumatoid Arthritis and No or Limited Exposure to
Methotrexate (Presenting author: Lorena
Gamboa) Abstract: THU0109
Friday, June 15, 11:45 –
13:30 CET – POSTER PRESENTATIONS
- Hepatic Safety in Patients with Rheumatic Arthritis Who
Received Isoniazid for Latent Tuberculosis: Post-Hoc Analysis from
Phase 3 Baricitinib Studies (Presenting author: Tsu-Yi Hsieh) Abstract: FRI0098
- Converting Patient-Reported Physical Function Outcomes Scores
to PROMIS Metric Scores in Phase 3 Trials of Baricitinib in
Rheumatoid Arthritis (Presenting author: Bing Bingham) Abstract:
FRI0013
- Hepatitis B Virus Reactivation in Patients with Rheumatoid
Arthritis Treated with Baricitinib: Post-Hoc Analysis from Clinical
Trials (Presenting author: Masayoshi Harigai) Abstract:
FRI0077
Saturday, June 16, 10:30 – 12 CET
– POSTER PRESENTATIONS
- Efficacy and Safety of Baricitinib in MTX-IR Patients with
Rheumatoid Arthritis: 52-Week Results from a Phase 3 Study
(Presenting author: Zhichang Li) Abstract: SAT0218
- Efficacy of Baricitinib in Patients with Rheumatoid Arthritis
Who Failed 2 or More DMARDs (Presenting author: Mark Genovese) Abstract: SAT0237
- Comparative Effectiveness in Pain and HAQ-DI Improvement for
Baricitinib Versus Adalimumab, Tocilizumab and Tofacitinib
Monotherapies in csDMARD-Naïve Rheumatoid Arthritis Patients: A
Matching-Adjusted Indirect Comparison (Presenting author: Bruno
Fautrel) Abstract: SAT0225
- Dose Reduction of Baricitinib in Patients with Rheumatoid
Arthritis Achieving Sustained Disease Control: Results of a
Prospective Study (Presenting author: Tsutomu Takeuchi) Abstract: SAT0253
PUBLISHED ONLY – NO PRESENTATION
- Impact of Controlling Disease Activity on Regaining Normal
Physical Function, and Achieving No or Limited Pain in Patients
with Rheumatoid Arthritis Treated with Baricitinib (Lead author:
Kurt de Vlam) Abstract:
AB0258
Taltz Data
Thursday, June 14, 11:45–
13:30 CET – POSTER PRESENTATIONS
- Efficacy and Safety of Ixekizumab in Patients with Active
Psoriatic Arthritis: Three Year Results from a Phase 3 Study
(SPIRIT-P1) (Presenting author: Vinod
Chandran) Abstract: THU0333
- Ixekizumab Makes Very Low Disease Activity and Remission with
Psoriatic Arthritis Disease Activity Score Possible in Active
Psoriatic Arthritis Patients for Up to One Year: SPIRIT-P1 and
SPIRIT-P2 Trials (Presenting author: Laura
Coates) Abstract: THU3014
- Ixekizumab Improves Nail and Skin Lesions Through 52 Weeks in
Patients with Active Psoriatic Arthritis and Inadequate
Response to Tumor Necrosis Factor Inhibitors (Presenting
author: Adeline Ruyssen-Witrand) Abstract: THU0313
Saturday, June 16 10:30 – 12 CET –
POSTER PRESENTATIONS
- Safety of Ixekizumab in Patients with Psoriatic Arthritis:
Results from a Pooled Analysis of Three Clinical Trials (Presenting
author: Philippe Goupille) Abstract:
SAT0348
- Ixekizumab Treatment Resolves Enthesitis and Dactylitis in
Patients with Active Psoriatic Arthritis: Results from the SPIRIT
Trials (Presenting author: Dafna
Gladman) Abstract: SAT0321
- Efficacy and Safety of Ixekizumab in Patients with Active
Psoriatic Arthritis and Previous Inadequate Response to TNF
inhibitors: 52-week Results from a Phase 3 Study (Presenting
author: Mark Genovese) Abstract:
SAT0341
PUBLISHED ONLY – NO PRESENTATION
- Ixekizumab Improves Fatigue in Patients with Psoriatic
Arthritis (Lead author: Ana-Maria
Orbai) Abstract: AB0906
- Efficacy and Safety of Ixekizumab When Used Alone or in
Combination with Conventional Disease-Modifying Anti-Rheumatic
Drugs (DMARDs) in TNF-Experienced Patients with Psoriatic Arthritis
(Lead author: Peter Nash) Abstract:
AB0944
Additional Data
Thursday, June 14, 11:45 –
13:30 CET – POSTER PRESENTATIONS
- Real World (RW) Experience with an Anti-IL-17A Inhibitor in
Biologic Naïve and Biologic Experienced Psoriatic Arthritis (PsA)
Patients (Presenting author: Rachel
Moon) Abstract: THU0327
- Effects of Biologic DMARDs on Physical Function in Patients
with Active Psoriatic Arthritis: Results of Network
Meta-Analyses (Presenting author: Adeline Ruyssen-Witrand)
Abstract: THU0290
- Factors Associated with High-Dose Corticosteroid Use in SLE
Patients Post Initiation of SLE Therapy (Presenting author:
Robert Hoffman) Abstract:
THU0374
Friday, June 15, 11:45 –
13:30 CET – POSTER PRESENTATIONS
- The Role of Pain in Rheumatoid Arthritis (RA) Patients'
Assessments of Their Health (Presenting author: Patricia Katz) Abstract: FRI0080
- The Impact of Disease Activity and Pain Level on Productivity
in Rheumatoid Arthritis (RA) Patients (Presenting author:
James Galloway) Abstract:
FRI0526
Saturday, June 16, 10:30 – 12 CET
– POSTER PRESENTATIONS
- Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients
Treated with Biologic and Non-Biologic DMARDs (Presenting author:
Judith Maro) Abstract: SAT0140
- Rapid and Sustained Improvements in Both Skin and
Musculoskeletal Symptoms Correlates with Improved Quality of Life
in Patients with Active Psoriatic Arthritis (Presenting author:
Arthur Kavanaugh) Abstract:
SAT0316
PUBLISHED ONLY – NO PRESENTATION
- Burden of Skin and Joint Symptoms of Psoriatic Disease: Results
of a Multi-National Patient Survey (Lead author: Joseph Merola) Abstract: AB0929
- Reduction in Fatigue and Pain Are Associated with Improved Work
Productivity in Patients with RA (Lead author: Janet Pope) Abstract: AB0240
- Towards Reforming the Taxonomy of Human Disease: The Preciseads
Cross Sectional Study (Lead author: Laurence Laigle) Abstract: AB1372
Indication and Usage for OLUMIANT (baricitinib) tablets (in
the United States) for RA
patients
OLUMIANT® (baricitinib) 2 mg is
indicated for the treatment of adult patients with moderately to
severely active rheumatoid arthritis who have had an inadequate
response to one or more tumor necrosis factor (TNF) antagonist
therapies. Limitation of Use: Use of OLUMIANT in combination
with other JAK inhibitors, biologic disease-modifying antirheumatic
drugs (DMARDs), or with potent immunosuppressants such as
azathioprine and cyclosporine is not recommended.
IMPORTANT SAFETY INFORMATION FOR OLUMIANT (baricitinib)
tablets
WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND
THROMBOSIS
SERIOUS INFECTIONS: Patients treated with
OLUMIANT are at risk for developing serious infections that may
lead to hospitalization or death. Most patients who developed these
infections were taking concomitant immunosuppressants such as
methotrexate or corticosteroids. If a serious infection develops,
interrupt OLUMIANT until the infection is controlled. Reported
infections include:
- Active tuberculosis (TB), which may present with pulmonary
or extrapulmonary disease. Test patients for latent TB before
initiating OLUMIANT and during therapy. Treatment for latent
infection should be considered prior to OLUMIANT use.
- Invasive fungal infections, including candidiasis and
pneumocystosis. Patients with invasive fungal infections may
present with disseminated, rather than localized, disease.
- Bacterial, viral, and other infections due to opportunistic
pathogens.
Carefully consider the risks and benefits of OLUMIANT prior
to initiating therapy in patients with chronic or recurrent
infection.
Closely monitor patients for the development of signs and
symptoms of infection during and after treatment with OLUMIANT,
including the possible development of TB in patients who tested
negative for latent TB infection prior to initiating
therapy.
MALIGNANCIES: Lymphoma and other malignancies
have been observed in patients treated with OLUMIANT.
THROMBOSIS: Thrombosis, including deep venous
thrombosis (DVT) and pulmonary embolism (PE), has been observed at
an increased incidence in patients treated with OLUMIANT compared
to placebo. In addition, there were cases of arterial thrombosis.
Many of these adverse events were serious and some resulted in
death. Patients with symptoms of thrombosis should be promptly
evaluated.
WARNINGS AND PRECAUTIONS
SERIOUS INFECTIONS: The most common serious infections
reported with OLUMIANT included pneumonia, herpes zoster, and
urinary tract infection. Among opportunistic infections,
tuberculosis, multidermatomal herpes zoster, esophageal
candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis,
cytomegalovirus, and BK virus were reported with OLUMIANT. Some
patients have presented with disseminated rather than local
disease, and were often taking concomitant immunosuppressants such
as methotrexate or corticosteroids. Avoid OLUMIANT in patients with
an active, serious infection, including localized infections.
Consider the risks and benefits of treatment prior to initiating
OLUMIANT in patients:
- with chronic or recurrent infection
- who have been exposed to TB
- with a history of a serious or an opportunistic infection
- who have resided or traveled in areas of endemic tuberculosis
or endemic mycoses; or
- with underlying conditions that may predispose them to
infection.
Monitor patients for infections during and after OLUMIANT
treatment. Interrupt OLUMIANT if a patient develops a serious
infection, an opportunistic infection, or sepsis. Do not resume
OLUMIANT until the infection is controlled.
Tuberculosis – Before initiating OLUMIANT,
evaluate and test patients for latent or active infection and treat
patients with latent TB with standard antimicrobial therapy.
OLUMIANT should not be given to patients with active TB. Consider
anti-TB therapy prior to initiating OLUMIANT in patients with a
history of latent or active TB in whom an adequate course of
treatment cannot be confirmed, and for patients with a negative
test for latent TB but who have risk factors for TB infection.
Monitor patients for TB during OLUMIANT treatment.
Viral Reactivation – Viral reactivation, including
cases of herpes virus reactivation (e.g., herpes zoster), were
reported in clinical studies with OLUMIANT. If a patient develops
herpes zoster, interrupt OLUMIANT treatment until the episode
resolves.
The impact of OLUMIANT on chronic viral hepatitis reactivation
is unknown. Screen for viral hepatitis in accordance with clinical
guidelines before initiating OLUMIANT.
MALIGNANCY AND LYMPHOPROLIFERATIVE DISORDERS:
Malignancies were observed in OLUMIANT clinical studies. Consider
the risks and benefits of OLUMIANT prior to initiating therapy in
patients with a known malignancy other than a successfully treated
non-melanoma skin cancer (NMSC) or when considering continuing
OLUMIANT in patients who develop a malignancy. NMSCs were reported
in patients treated with OLUMIANT. Periodic skin examination is
recommended for patients who are at increased risk for skin
cancer.
THROMBOSIS: Thrombosis, including DVT and
PE, has been observed at an increased incidence in OLUMIANT-treated
patients compared to placebo. In addition, arterial thrombosis
events in the extremities have been reported in clinical studies
with OLUMIANT. Many of these adverse events were serious and some
resulted in death. There was no clear relationship between platelet
count elevations and thrombotic events. Use OLUMIANT with caution
in patients who may be at increased risk of thrombosis. If clinical
features of DVT/PE or arterial thrombosis occur, evaluate patients
promptly and treat appropriately.
GASTROINTESTINAL PERFORATIONS: Gastrointestinal
perforations have been reported in OLUMIANT clinical studies,
although the role of JAK inhibition in these events is not known.
Use OLUMIANT with caution in patients who may be at increased risk
for gastrointestinal perforation (e.g., patients with a history of
diverticulitis). Promptly evaluate patients who present with new
onset abdominal symptoms for early identification of
gastrointestinal perforation.
LABORATORY ABNORMALITIES:
Neutropenia – OLUMIANT treatment was associated
with an increased incidence of neutropenia (absolute neutrophil
count [ANC] <1000 cells/mm3) compared to
placebo. Avoid initiation or interrupt OLUMIANT treatment in
patients with an ANC <1000 cells/mm3. Evaluate
at baseline and thereafter according to routine patient
management.
Lymphopenia – Absolute lymphocyte count (ALC)
<500 cells/mm3 were reported in OLUMIANT
clinical trials. Lymphocyte counts less than the lower limit of
normal were associated with infection in patients treated with
OLUMIANT, but not placebo. Avoid initiation or interrupt OLUMIANT
treatment in patients with an ALC
<500 cells/mm3. Evaluate at baseline and
thereafter according to routine patient management.
Anemia – Decreases in hemoglobin levels to
<8 g/dL were reported in OLUMIANT clinical trials. Avoid
initiation or interrupt OLUMIANT treatment in patients with
hemoglobin <8 g/dL. Evaluate at baseline and thereafter
according to routine patient management.
Liver Enzyme Elevations – OLUMIANT treatment was
associated with increased incidence of liver enzyme elevation
compared to placebo. Increases to ≥5x and ≥10x upper limit of
normal were observed for both ALT and AST in patients in OLUMIANT
clinical trials.
Evaluate at baseline and thereafter according to routine patient
management. Promptly investigate the cause of liver enzyme
elevation to identify potential cases of drug-induced liver injury.
If increases in ALT or AST are observed and drug-induced liver
injury is suspected, interrupt OLUMIANT until this diagnosis is
excluded.
Lipid Elevations – Treatment with OLUMIANT was
associated with increases in lipid parameters, including total
cholesterol, low-density lipoprotein cholesterol, and high-density
lipoprotein cholesterol. Assess lipid parameters approximately
12 weeks following OLUMIANT initiation. Manage patients
according to clinical guidelines for the management of
hyperlipidemia.
VACCINATIONS: Avoid use of live vaccines with
OLUMIANT. Update immunizations in agreement with current
immunization guidelines prior to initiating OLUMIANT therapy.
ADVERSE REACTIONS
Adverse reactions (≥1%) include: upper respiratory tract
infections (16.3%, 14.7%, 11.7%), nausea (2.7%, 2.8%, 1.6%), herpes
simplex (0.8%, 1.8%, 0.7%), and herpes zoster (1.0%, 1.4%, 0.4%)
for OLUMIANT 2 mg, baricitinib 4 mg, and placebo, respectively.
USE IN SPECIFIC POPULATIONS
PREGNANCY AND LACTATION: No information is available to
support the use of OLUMIANT in pregnancy or lactation. Advise women
not to breastfeed during treatment with OLUMIANT.
HEPATIC AND RENAL IMPAIRMENT: OLUMIANT is not recommended
in patients with severe hepatic impairment or in patients with
moderate or severe renal impairment.
Please click to access full Prescribing
Information, including Boxed Warning about Serious
infections, Malignancies, and Thrombosis, and Medication
Guide.
BA HCP ISI 01JUN2018
INDICATIONS AND USAGE FOR TALTZ
Taltz is
approved for the treatment of adults with active psoriatic
arthritis. Taltz is also approved to treat adults with moderate to
severe plaque psoriasis who are candidates for systemic therapy or
phototherapy.
IMPORTANT SAFETY INFORMATION FOR TALTZ
CONTRAINDICATIONS
Taltz is contraindicated in
patients with a previous serious hypersensitivity reaction, such as
anaphylaxis, to ixekizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Infections
Taltz
may increase the risk of infection. In clinical trials of patients
with plaque psoriasis, the Taltz group had a higher rate of
infections than the placebo group (27% vs 23%). A similar increase
in risk of infection was seen in placebo-controlled trials of
patients with psoriatic arthritis. Serious infections have
occurred. Instruct patients to seek medical advice if signs or
symptoms of clinically important chronic or acute infection occur.
If a serious infection develops, discontinue Taltz until the
infection resolves.
Pre-Treatment Evaluation for Tuberculosis
Evaluate
patients for tuberculosis (TB) infection prior to initiating
treatment with Taltz. Do not administer to patients with active TB
infection. Initiate treatment of latent TB prior to administering
Taltz. Closely monitor patients receiving Taltz for signs and
symptoms of active TB during and after treatment.
Hypersensitivity
Serious hypersensitivity reactions,
including angioedema and urticaria (each ≤0.1%), occurred in the
Taltz group in clinical trials. Anaphylaxis, including cases
leading to hospitalization, has been reported in post-marketing use
with Taltz. If a serious hypersensitivity reaction occurs,
discontinue Taltz immediately and initiate appropriate therapy.
Inflammatory Bowel Disease
Crohn's disease and
ulcerative colitis, including exacerbations, occurred at a greater
frequency in the Taltz group (Crohn's disease 0.1%, ulcerative
colitis 0.2%) than in the placebo group (0%) during clinical trials
in patients with plaque psoriasis. During Taltz treatment, monitor
patients for onset or exacerbations of inflammatory bowel
disease.
Immunizations
Prior to initiating therapy with Taltz,
consider completion of all age-appropriate immunizations according
to current immunization guidelines. Avoid use of live vaccines in
patients treated with Taltz.
ADVERSE REACTIONS
Most common adverse reactions
(>1%) associated with Taltz treatment are injection site
reactions, upper respiratory tract infections, nausea, and tinea
infections. Overall, the safety profile observed in patients with
psoriatic arthritis was consistent with the safety profile in
patients with plaque psoriasis, with the exception of influenza and
conjunctivitis.
Please see accompanying Prescribing
Information and Medication
Guide. Please see Instructions for Use
included with the device.
IX HCP ISI 01DEC2017
About Systemic Lupus Erythematosus
Systemic lupus
erythematosus (SLE) is a chronic, multi-organ autoimmune disease
that can cause widespread tissue and organ damage.1 SLE
is characterized by periods of flare and remission and is
associated with a variety of symptoms, including extreme fatigue,
unexplained fever, joint pain/swelling and butterfly
rash.1,2 Approximately 90 percent of all cases occur in
women at a time when life and family demands are
greatest.3
About Psoriatic Arthritis
Psoriatic arthritis (PsA) is
a chronic, progressive form of inflammatory arthritis that can
cause swelling, stiffness and pain in and around the joints and
impaired physical function.4 It occurs when an
overactive immune system sends out faulty signals that cause
inflammation, leading to swollen and painful joints and
tendons.6 Psoriatic arthritis can affect peripheral
joints in the arms and legs (elbows, wrists, hands and
feet).6 If left untreated, PsA can cause permanent joint
damage.6 Up to 30 percent of people with psoriasis also
develop PsA.6
About Rheumatoid Arthritis
Rheumatoid arthritis is a
systemic autoimmune disease characterized by inflammation and
progressive destruction of joints.5,6 Approximately
three times as many women as men have the
disease.7 Current treatment of RA includes the use
of non-steroidal anti-inflammatory drugs, oral conventional
synthetic disease-modifying antirheumatic drugs (csDMARDs) — such
as methotrexate, the current standard of care, and injectable,
biological disease-modifying antirheumatic drugs (bDMARDs) that
target selected mediators implicated in the pathogenesis of
RA.8 Despite current treatment options, many
patients do not reach their therapeutic goals.8,9 There
remains an important need to provide additional treatment options
to improve overall patient care.
About OLUMIANT
OLUMIANT is a once-daily, oral JAK
inhibitor for the treatment of adults with moderately-to-severely
active rheumatoid arthritis who have had an inadequate response to
one or more TNF inhibitor therapies.10 There are four
known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent
cytokines have been implicated in the pathogenesis of a number of
inflammatory and autoimmune diseases.11 OLUMIANT has
greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3;
however, the relevance of inhibition of specific JAK enzymes to
therapeutic effectiveness is not currently known.11
OLUMIANT is approved in more than 40 countries.
About Taltz
Taltz (ixekizumab) is a monoclonal
antibody that selectively binds with interleukin 17A (IL-17A)
cytokine and inhibits its interaction with the IL-17
receptor.12 IL-17A is a naturally occurring cytokine
that is involved in normal inflammatory and immune
responses. Taltz inhibits the release of
pro-inflammatory cytokines and chemokines.13
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
newsroom.lilly.com/social-channels. P-LLY
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about OLUMIANT (baricitinib) as a treatment for patients with
rheumatoid arthritis and a potential treatment for systemic lupus
erythematosus and Taltz (ixekizumab) as a treatment for active
psoriatic arthritis. These statements reflect Lilly's current
belief. As with any pharmaceutical products, however, there are
substantial risks and uncertainties in the process of development
and commercialization. Among other things, there can be no
guarantee that future study results will be consistent with the
results to date, that baricitinib or ixekizumab will receive
additional regulatory approvals or will be commercially successful.
For further discussion of these and other risks and uncertainties,
see Lilly's most recent Form 10-K and Form 10-Q filings with the
United States Securities and Exchange Commission. Except as
required by law, Lilly undertakes no duty to update forward-looking
statements to reflect events after the date of this
release.
Refer to:
|
Danielle Neveles;
danielle.neveles@lilly.com; +1-317-796-4564 (Lilly
media)
|
|
Kevin Hern;
hern_kevin_r@lilly.com; 317-277-1838 (Lilly investors)
|
1 Kyttaris VC. Systemic Lupus Erythematosus: From
Genes to Organ Damage. Methods in molecular biology (Clifton, NJ). 2010;662:265-283.
doi:10.1007/978-1-60761-800-3_13.
2 Dubois EL, Tuffanelli DL. Clinical Manifestations of
Systemic Lupus Erythematosus: Computer Analysis of 520 Cases. JAMA.
1964;190(2):104–111. doi:10.1001/jama.1964.03070150014003
3 Lupus Foundation of America, Lupus facts and
statistics, https://resources.lupus.org/entry/facts-and-statistics.
Accessed on June 7, 2018.
4 Ritchlin C, et. al. Psoriatic Arthritis. New
England Journal of Medicine. 2017;376:957-70.
5 Klareskog L, Catrina AI, Paget S. Lancet.
2009;373:659-672.
6 Hand Clinics, Advances in the Medical Treatment
of Rheumatoid Arthritis,
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135413/pdf/nihms305780.pdf.
Accessed June 4, 2018.
7 Hunter TM, et al. Rheumatol Int.
2017;37:1551–1557.
8 Smolen JS, Aletaha D, McInnes IB. Lancet.
2016;388:2023-2038.
9 Sustained Rheumatoid Arthritis Remission is
Uncommon in Clinical Practice, Arthritis Research & Therapy,
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446437/. Accessed
June 4, 2018.
10 Olumiant [package insert]. Indianapolis, IN: Eli Lilly and Company;
2018.
11 Walker JG and Smith MD. J Rheumatol.
2005;32;1650-1653.
12 Taltz Prescribing Information, 2018.
View original content with
multimedia:http://www.prnewswire.com/news-releases/lilly-to-unveil-new-data-at-the-annual-european-congress-of-rheumatology-furthering-commitment-to-scientific-discovery-in-immunology-300663792.html
SOURCE Eli Lilly and Company